Young streak off a low base: a short run of consecutive-period improvement has just started, after a stretch that gave i
The model's full reasoning — Q1 2022 call → NO我们根据提供的财报电话会议记录,判断管理层是否传达了业务中某个部分已经连续几个季度(大约2到4个季度)出现真实改善,且这种改善的原因与公司自身有关并仍在发挥作用。 首先,寻找相关的业务部分。记录中,Jon Cohen(BioReference Laboratories)的发言提到:“Our commercial payer interactions continue to be successful with our preferred status with Aetna, which became effective on the 1st of this year.” 以及“Volume in our clinical base business increased 4% versus the fourth quarter, driven by our preferred status with UnitedHealthcare and Aetna.” 这是核心诊断业务(非COVID)的改善,比较的是与上季度(Q4 2021)相比增加4%。此外,还提到“Our women's health business, our noninvasive prenatal testing business grew substantially up almost 16,000 samples year-over-year or a 219% increase.” 但这是同比。 关键点:核心临床业务与上季度相比增长了4%,这至少是连续两个季度的改善吗?记录中并未明确说这是连续几个季度的改善。只说“increased 4% versus the fourth quarter”,即比Q4增长4%,但Q4相对于Q3如何?没有信息。所以没有明确说明连续几个季度。 再看其他部分:关于COVID测试量,Q1 2022为2百万,Q4 2021为2.7百万,这是下降。所以COVID业务是下降的。但Jon提到“As COVID testing has waned, BioReference continues to focus on its strategy to grow our core diagnostic business”。因此核心业务在增长,但只有Q1相对于Q4的一个改善,没有提到之前连续改善。 另外,关于OncoCyte测试:“Cancer Genetics largely made up of our OncoCyte suite of testing has more than doubled in volume in the last 12 months.” 这是过去12个月翻倍,但没有连续季度。 关于Women's health NIPT:同比增长219%,但同比不算连续。 关于Scarlet Health:提到推出一年多,但未说连续改善。 所以,没有明确的管理层描述连续几个季度(两个以上)的改善。只有一个季度(Q1)相对Q4增长4%,但没提Q4相对Q3,所以无法确定连续。 此外,管理层在总结时提到“we expect our core clinical laboratory business will continue to improve”,但这是期望,不是已经发生的连续。 因此,不满足“连续几个季度”的条件。 另外,再考虑是否有其他部分?比如Pharmaceuticals segment?营收从Q1 2021的38.2百万到Q1 2022的42.6百万,但这是同比,不是环比。而且没有提到连续。 因此,答案应为NO。 再确认是否有“young run”描述?没有。 所以回答NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| OLPX | Olaplex Holdings, Inc. | Q4 2023 | 2024-02-29 | D |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| BMBL | Bumble Inc. | Q3 2023 | 2023-11-07 | F |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| LEG | Leggett & Platt, Incorporated | Q3 2021 | 2021-11-02 | C |
| UFI | Unifi, Inc. | Q4 2021 | 2021-08-07 | B |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| SPR | Spirit AeroSystems Holdings, Inc. | Q1 2016 | 2016-04-29 | D |
WRBY · Q1 2024 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...
ASB · Q1 2024 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...
KOPN · Q4 2023 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...